Upon discovery of cases of tuberculosis coinciding with the market launch of the TNF blockers, screening for LTBI was mostly carried out in the approval and dose-finding studies around the T‐cell co-stimulation inhibitor abatacept. This evidence concerns the gene TNF and tuberculosis.